Monoclonal Antibody Deal Benchmarks in Metabolic & Obesity
Market Analysis
Monoclonal Antibody therapies in metabolic & obesity have seen significant M&A and licensing activity in recent years. Based on analysis of 1,400+ verified transactions, the median upfront payment for a Phase 2 monoclonal antibody asset in metabolic & obesity is $703M, with total deal values reaching $3.3B. Development milestones average $474M, while regulatory milestones contribute $579M.
The metabolic & obesity monoclonal antibody landscape is characterized by extremely high competitive intensity driven by the GLP-1 revolution and massive obesity market opportunity. Oral formulations, dual/triple incretins, and muscle-sparing approaches command unprecedented deal valuations. The recommended deal structure allocates approximately 21% to upfront payments and 79% to milestones, reflecting the risk-reward profile at the Phase 2 stage.
Royalty rates for monoclonal antibody metabolic & obesity deals range from 14.7% to 26.9% at the base tier, with tiered escalation reaching 18.7%-30.9% on blockbuster sales. Commercial milestones averaging $1.6B further reward successful market penetration.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What is the typical upfront for a monoclonal antibody metabolic & obesity licensing deal?
What is the total deal value for monoclonal antibody metabolic & obesity transactions?
What royalty rates are standard for monoclonal antibody deals in metabolic & obesity?
How are milestones structured in monoclonal antibody metabolic & obesity deals?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
Start 7-Day Free Trial$299/mo after trial · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 1,400+ biopharma licensing deals.
Start CalculatingNeed a decision for one asset?
The Deal Intelligence Brief turns this landscape into a decision for one asset — a signed recommendation with ask, floor and walk-away, cited comparables, buyers ranked on evidence, and a 24-month catalyst calendar. Reviewed by the Managing Partner; delivered within 24 hours of the intake call.